Oncology Biosimilars Market Report 2025-2033 | Cost-Effective Biologics Drive Patient Access, Competition, and Healthcare Savings [Yahoo! Finance]
Dr. Reddy's Laboratories Ltd (RDY)
US:NYSE Investor Relations:
drreddys.com/investors
Company Research
Source: Yahoo! Finance
Biosimilars can lower treatment costs, improve access, and increase competition. Growth is expected across drug types, cancer types, distribution channels, and regions, driven by patent expiries and R&D efforts. Oncology Biosimilars Market Oncology Biosimilars Market Dublin, Sept. 12, 2025 (GLOBE NEWSWIRE) -- The "Oncology Biosimilars Market Report by Drug Type, and Region 2025-2033" has been added to ResearchAndMarkets.com's offering. The global oncology biosimilars market is on a trajectory of robust expansion, with its value anticipated to soar from USD 5.8 billion in 2024 to USD 35.2 billion by 2033. This period will witness a compound annual growth rate (CAGR) of 21.15% from 2025 to 2033. The impetus behind this growth stems from a rising geriatric population and environmental changes that have escalated cancer incidences worldwide, coupled with the increasingly high costs of cancer treatment burdening healthcare systems globally. Oncology biosimilars present a cost-e
Show less
Read more
Impact Snapshot
Event Time:
RDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDY alerts
High impacting Dr. Reddy's Laboratories Ltd news events
Weekly update
A roundup of the hottest topics
RDY
News
- Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid MalignanciesBusiness Wire
- ValGenesis Wraps Up Global ValConnect Innovation Day Series with Hyderabad Event [Yahoo! Finance]Yahoo! Finance
- Dr. Reddy's Laboratories Limited (RDY) Q2 2026 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Dr. Reddy's Laboratories (NYSE:RDY) had its "buy (b-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025Business Wire
RDY
Earnings
- 7/24/25 - Beat
RDY
Sec Filings
- 12/3/25 - Form 6-K
- 11/28/25 - Form 6-K
- 11/28/25 - Form 6-K
- RDY's page on the SEC website